Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Rebukes Egalet's Reliance On OxyContin Postmarketing Data

Executive Summary

Arymo ER sponsor's consultants said Purdue's postmarketing data on its reformulated oxycodone establish a link between abuse-deterrent properties and reduced real-world abuse, but FDA says it disagreed with the conclusion in the context of an OxyContin labeling supplement.


Related Content

Remoxy Review Leaves US FDA Wondering: Where Is The Real-World Data On ADFs?
Abuse-Deterrent Opioids: Postmarketing Data Eyed As Development ‘Anchor’
Egalet's Arymo ER Opioid Has Questionable Oral Abuse-Deterrent Effect
Purdue's Pain And No Gain: More Analysis Of OxyContin Postmarket Studies Needed


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts